Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Int J Surg. 2022 Oct;106:106891. doi: 10.1016/j.ijsu.2022.106891. Epub 2022 Sep 20.
Pancreatic ductal adenocarcinoma (PDAC) is prone to relapse even after radical pancreaticoduodenectomy (PD) (including robotic, laparoscopic and open approach). This study aimed to develop an online nomogram calculator to predict early recurrence (ER) (within one year after surgery) and long-term survival in patients with PDAC.
Patients with PDAC after radical PD were included. Univariate and multivariate logistic regression analysis was used to identify independent risk factors. An online nomogram calculator was developed based on independent risk factors in the training cohort and then tested in the internal and external validation cohorts.
Of the 569 patients who met the inclusion criteria, 310, 155, and 104 patients were in the training, internal and external validation cohorts, respectively. Multivariate analysis revealed that preoperative carbohydrate antigen19-9 (CA19-9) [Odds Ratio (OR) 1.002; 95% confidence interval (CI) 1.001-1.003; P = 0.001], fibrinogen/albumin (FAR) (OR 1.132; 95% CI 1.012-1.266; P = 0.029), N stage (OR 2.291; 95% CI 1.283-4.092; P = 0.005), and tumor differentiation (OR 3.321; 95% CI 1.278-8.631; P = 0.014) were independent risk factors for ER. Nomogram based on the above four factors achieved good C-statistics of 0.772, 0.767 and 0.765 in predicting ER in the training, internal and external validation cohorts, respectively. Time-dependent ROC analysis (timeROC) and decision curve analysis (DCA) revealed that the nomogram provided superior diagnostic capacity and net benefit compared with other staging systems.
This multi-center study developed and validated an online nomogram calculator that can predict ER and long-term survival in patients with PDAC with high degrees of stability and accuracy.
即使在根治性胰十二指肠切除术(PD)后(包括机器人、腹腔镜和开放方法),胰腺导管腺癌(PDAC)也容易复发。本研究旨在开发一种在线列线图计算器,以预测 PDAC 患者的早期复发(ER)(术后 1 年内)和长期生存。
纳入根治性 PD 后 PDAC 患者。采用单因素和多因素 logistic 回归分析确定独立危险因素。基于训练队列中的独立危险因素开发在线列线图计算器,然后在内部和外部验证队列中进行测试。
符合纳入标准的 569 例患者中,310 例、155 例和 104 例患者分别纳入训练、内部和外部验证队列。多因素分析显示,术前糖类抗原 19-9(CA19-9)[比值比(OR)1.002;95%置信区间(CI)1.001-1.003;P=0.001]、纤维蛋白原/白蛋白(FAR)(OR 1.132;95%CI 1.012-1.266;P=0.029)、N 分期(OR 2.291;95%CI 1.283-4.092;P=0.005)和肿瘤分化(OR 3.321;95%CI 1.278-8.631;P=0.014)是 ER 的独立危险因素。基于上述四个因素的列线图在预测训练、内部和外部验证队列中的 ER 方面取得了良好的 C 统计量,分别为 0.772、0.767 和 0.765。时间依赖性 ROC 分析(timeROC)和决策曲线分析(DCA)表明,与其他分期系统相比,该列线图具有更高的诊断能力和净获益。
本多中心研究开发并验证了一种在线列线图计算器,可高度稳定和准确地预测 PDAC 患者的 ER 和长期生存。